Ovarian cancers often overexpress a range of TAAs such as FRα, mucin 16 [MUC16; cancer antigen 125 (CA-125)], and mesothelin, making them ideal targets for bsAb development [50, 51]. This evidence concerns the gene MUC16 and ovarian carcinoma.